CTD-ILD: Rituximab 'a Reasonable Alternative to Cyclophosphamide'

A clinical trial found that rituximab and cyclophosphamide had similar outcomes for interstitial lung disease associated with connective tissue disorders.
MDedge News

source https://www.medscape.com/viewarticle/983976?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost